Workflow
预盈预增
icon
Search documents
涛涛车业涨2.30%,成交额6503.71万元,主力资金净流入685.71万元
Xin Lang Cai Jing· 2025-08-22 03:13
Core Viewpoint - TaoTao Automotive has shown significant stock price appreciation and strong financial performance, indicating potential growth in the outdoor leisure and short-distance transportation market [1][2]. Financial Performance - As of August 8, 2023, TaoTao Automotive reported a revenue of 639 million yuan for Q1 2025, representing a year-on-year growth of 22.96% [2]. - The company has distributed a total of 545 million yuan in dividends since its A-share listing [2]. Stock Performance - The stock price has increased by 195.41% year-to-date, with a 12.73% rise over the last five trading days and a 17.51% increase over the last 20 days [2]. - As of August 22, 2023, the stock was trading at 189.37 yuan per share, with a market capitalization of 20.572 billion yuan [1]. Shareholder Information - The number of shareholders decreased by 8.19% to 8,336 as of August 8, 2023, while the average number of circulating shares per person increased by 8.93% to 3,440 shares [2]. - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 709,000 shares, a decrease of 1.0162 million shares from the previous period [2]. Market Position - TaoTao Automotive operates in the motorcycle and other automotive sectors, categorized under the "Automobile - Motorcycle and Others - Motorcycle" industry by Shenwan [2]. - The company is associated with several concept sectors, including historical highs, specialized and innovative enterprises, and strong annual performance [2].
纳微科技涨2.11%,成交额4903.01万元,主力资金净流出180.19万元
Xin Lang Cai Jing· 2025-08-22 03:13
Core Viewpoint - Nanwei Technology's stock has shown significant growth this year, with a 60.18% increase, indicating strong market performance and investor interest [1]. Group 1: Stock Performance - As of August 22, Nanwei Technology's stock price reached 28.09 CNY per share, with a market capitalization of 11.343 billion CNY [1]. - The stock has experienced a 3.27% increase over the last five trading days, a 2.41% increase over the last 20 days, and a 33.91% increase over the last 60 days [1]. - Year-to-date, the stock has appeared on the trading leaderboard once, with a net buy of -5.5156 million CNY on February 27 [1]. Group 2: Financial Performance - For the period from January to March 2025, Nanwei Technology reported a revenue of 189 million CNY, reflecting a year-on-year growth of 22.39% [2]. - The company has distributed a total of 115 million CNY in dividends since its A-share listing, with 86.8418 million CNY distributed over the past three years [2]. Group 3: Shareholder Information - As of March 31, 2025, the number of shareholders for Nanwei Technology was 14,800, a decrease of 0.99% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.00% to 27,351 shares [2]. - Among the top ten circulating shareholders, the China Europe Medical Health Mixed A fund is a new entrant, holding 8.6703 million shares [2].
瑞普生物跌2.01%,成交额9328.16万元,主力资金净流出790.21万元
Xin Lang Cai Jing· 2025-08-22 03:12
Company Overview - Reap Bio is located in Tianjin Free Trade Zone and was established on August 2, 2001, with its listing date on September 17, 2010 [1] - The company specializes in veterinary biological products (animal vaccines) and chemical pharmaceuticals [1] Stock Performance - As of August 22, Reap Bio's stock price decreased by 2.01%, trading at 22.93 CNY per share, with a total market capitalization of 10.657 billion CNY [1] - Year-to-date, the stock price has increased by 26.85%, with a 0.66% rise over the last five trading days, a 4.61% increase over the last 20 days, and a 7.02% decline over the last 60 days [1] Financial Performance - For the period from January to March 2025, Reap Bio reported a revenue of 822 million CNY, representing a year-on-year growth of 54.09% [2] - The company has distributed a total of 1.371 billion CNY in dividends since its A-share listing, with 462 million CNY distributed over the last three years [2] Shareholder Information - As of August 8, the number of shareholders for Reap Bio was 27,000, with an average of 12,406 circulating shares per shareholder [2] - As of March 31, 2025, the fifth largest circulating shareholder is Harvest Agricultural Industry Stock A, holding 6.3889 million shares, an increase of 696,900 shares from the previous period [2] Market Activity - On August 22, the net outflow of main funds was 7.9021 million CNY, with large orders accounting for 15.94% of purchases and 21% of sales [1]
步长制药跌2.03%,成交额1.01亿元,主力资金净流出731.79万元
Xin Lang Cai Jing· 2025-08-22 03:11
Company Overview - Shandong Buchang Pharmaceutical Co., Ltd. is located in Mudan District, Heze City, Shandong Province, established on May 10, 2001, and listed on November 18, 2016. The company specializes in the research, production, and sales of traditional Chinese medicine [1][2]. Stock Performance - As of August 22, Buchang Pharmaceutical's stock price decreased by 2.03%, trading at 18.78 CNY per share, with a total market capitalization of 19.805 billion CNY. The stock has increased by 18.86% year-to-date, with a 1.95% rise over the last five trading days, 4.04% over the last twenty days, and 13.68% over the last sixty days [1]. Financial Performance - For the period from January to March 2025, Buchang Pharmaceutical reported a revenue of 2.785 billion CNY, reflecting a year-on-year growth of 5.47%. The company has cumulatively distributed 7.537 billion CNY in dividends since its A-share listing, with 1.197 billion CNY distributed over the last three years [2]. Shareholder Information - As of March 31, 2025, the number of shareholders for Buchang Pharmaceutical was 59,500, a decrease of 0.44% from the previous period. The average number of circulating shares per shareholder increased by 0.44% to 18,587 shares [2]. Institutional Holdings - Among the top ten circulating shareholders as of March 31, 2025, Hong Kong Central Clearing Limited ranked as the ninth largest shareholder, holding 7.8596 million shares, a decrease of 576,000 shares from the previous period [2].
恒生电子涨2.00%,成交额16.47亿元,主力资金净流入3319.61万元
Xin Lang Cai Jing· 2025-08-22 03:04
恒生电子今年以来股价涨36.97%,近5个交易日涨3.64%,近20日涨13.93%,近60日涨46.19%。 机构持仓方面,截止2025年3月31日,恒生电子十大流通股东中,香港中央结算有限公司位居第二大流通股东,持股1.48亿股,相比上期增加1286.04万股。华泰柏瑞沪深300ETF(510300) 责任编辑:小浪快报 8月22日,恒生电子盘中上涨2.00%,截至10:54,报38.20元/股,成交16.47亿元,换手率2.31%,总市值722.66亿元。 截至3月31日,恒生电子股东户数18.83万,较上期增加8.27%;人均流通股10047股,较上期减少7.75%。2025年1月-3月,恒生电子实现营业收入10.26亿元,同比减少13.62%;归母净利 分红方面,恒生电子A股上市后累计派现24.44亿元。近三年,累计派现6.82亿元。 资金流向方面,主力资金净流入3319.61万元,特大单买入2.42亿元,占比14.69%,卖出2.12亿元,占比12.88%;大单买入3.98亿元,占比24.14%,卖出3.94亿元,占比23.94%。 今年以来恒生电子已经1次登上龙虎榜,最近一次登上龙虎榜为6月16 ...
洛阳钼业涨0.92%,成交额19.42亿元,今日主力净流入6901.14万
Xin Lang Cai Jing· 2025-08-20 08:05
Core Viewpoint - The company, Luoyang Molybdenum Co., Ltd., is a significant player in the non-ferrous metal mining industry, focusing on various metals including molybdenum, tungsten, cobalt, and copper, with a comprehensive integrated industrial chain [2]. Company Overview - Luoyang Molybdenum Co., Ltd. was established on December 22, 1999, and listed on October 9, 2012. The company primarily engages in the mining, selection, smelting, deep processing, and trading of precious metals [6]. - The company's revenue composition includes refined metal products (58.08%), concentrates (30.34%), copper (19.65%), cobalt (4.10%), molybdenum (2.96%), phosphorus (1.68%), niobium (1.39%), tungsten (0.86%), and others [6]. Business Operations - The company is among the top five molybdenum producers globally and the largest tungsten producer, as well as the second-largest cobalt and niobium producer [2]. - The company holds a 30% stake in the 60,000-ton nickel metal wet smelting project in Indonesia, which commenced production in December last year and is currently ramping up capacity [2]. - The company has been expanding its precious metals business, with gold production from its NPM copper-gold mine in Australia expected to increase from 16,000 ounces in 2022 to a guidance of 25,000 to 27,000 ounces in 2023, representing a year-on-year growth of 56% to 69% [2]. Financial Performance - As of March 31, 2025, the company reported a revenue of 46.006 billion yuan, a slight decrease of 0.25% year-on-year, while the net profit attributable to shareholders increased by 90.47% to 3.946 billion yuan [7]. - The company has distributed a total of 21.562 billion yuan in dividends since its A-share listing, with 10.576 billion yuan in the last three years [8]. Market Activity - On August 20, the company's stock price increased by 0.92%, with a trading volume of 1.942 billion yuan and a turnover rate of 1.02%, resulting in a total market capitalization of 234.268 billion yuan [1].
德业股份上周获融资净买入5683.71万元,居两市第161位
Sou Hu Cai Jing· 2025-08-04 19:17
Core Viewpoint - The financing data for Deye Technology Co., Ltd. indicates a net financing inflow of 56.8371 million RMB last week, ranking 161st in the market, with a total financing purchase of 342 million RMB and repayment of 285 million RMB [1] Company Overview - Deye Technology Co., Ltd. was established in 2000 and is located in Ningbo City, primarily engaged in the manufacturing of computers, communications, and other electronic equipment [1] - The company has a registered capital of 638.110297 million RMB and a paid-in capital of 15.85 million RMB [1] - The legal representative of the company is Zhang Dong Ye [1] Investment and Intellectual Property - Deye Technology has invested in 19 companies and participated in 30 bidding projects [1] - The company holds 35 trademark registrations and 107 patents, along with 5 administrative licenses [1] Financial Performance - Over the past 5 days, the main capital outflow for Deye Technology was 216 million RMB, with a decline of 6.78% in this period [1] - Over the past 10 days, the main capital outflow was 264 million RMB, with a decline of 4.1% [1] Conceptual Segments - Deye Technology is associated with several concept sectors including photovoltaic equipment, Zhejiang sector, MSCI China, Shanghai Stock Connect, and energy storage [1]
杭州柯林上周获融资净买入5886.50万元,居两市第156位
Sou Hu Cai Jing· 2025-08-04 19:17
Core Insights - Hangzhou Kelin Electric Co., Ltd. has shown significant financing activity, with a net financing inflow of 58.865 million RMB last week, ranking 156th in the market [1] - The company operates in various sectors including power grid equipment, storage chips, and blockchain technology, indicating a diversified business model [1] Financing Activity - Last week, the total financing amount was 129 million RMB, while repayments amounted to approximately 69.9996 million RMB [1] - Over the past 5 days, the main capital inflow was 37.6169 million RMB, with a price increase of 5.37% [1] - In the last 10 days, the main capital inflow was 21.876 million RMB, with a price increase of 2.48% [1] Company Profile - Hangzhou Kelin Electric was established in 2002 and is located in Hangzhou, primarily engaged in the manufacturing of electrical machinery and equipment [1] - The company has a registered capital of 153.3896 million RMB and a paid-in capital of 41.925 million RMB [1] - The legal representative of the company is Xie Dong [1] Investment and Intellectual Property - The company has made investments in 4 enterprises and participated in 229 bidding projects [1] - It holds 15 trademark registrations and 288 patents, along with 13 administrative licenses [1]
海创药业上周获融资净买入7753.11万元,居两市第115位
Sou Hu Cai Jing· 2025-08-04 04:39
Core Viewpoint - Haichuang Pharmaceutical has shown significant financing activity, indicating potential investor interest and market confidence in the company [1] Financing Activity - Haichuang Pharmaceutical recorded a net financing inflow of 77.53 million RMB last week, ranking 115th in the market [1] - The total financing amount for the week was 210 million RMB, with repayments amounting to 132 million RMB [1] Capital Flow - Over the past 5 days, the main capital inflow into Haichuang Pharmaceutical was 47.83 million RMB, with a price increase of 3.91% [1] - In the last 10 days, the main capital inflow was 58.37 million RMB, with a price increase of 2.27% [1] Company Profile - Haichuang Pharmaceutical Co., Ltd. was established in 2013 and is located in Chengdu, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 990.16 million RMB and a paid-in capital of 690.11 million RMB [1] - The legal representative of the company is Yuanwei Chen [1] Investment and Intellectual Property - Haichuang Pharmaceutical has invested in 2 external companies and participated in 15 bidding projects [1] - The company holds 23 trademark registrations and 71 patents, along with 89 administrative licenses [1]
生益电子上周获融资净买入3282.19万元,居两市第287位
Sou Hu Cai Jing· 2025-08-04 04:39
Core Insights - The financing net inflow for Shengyi Electronics last week was 32.82 million yuan, ranking 287th in the market, with a total financing purchase amount of 688 million yuan and repayment amount of 655 million yuan [1] - The company operates in various sectors including electronic components, Guangdong region, Shanghai Stock Connect, CSI 500, margin trading, pre-profit growth, AIPC, PCB, Huawei concept, and autonomous driving [1] Financial Data - Over the past 5 days, the main capital outflow for Shengyi Electronics was 51.77 million yuan, with a decline of 0.74% during this period [1] - Over the past 10 days, the main capital outflow reached 124 million yuan, with a decline of 1.17% [1] Company Overview - Shengyi Electronics Co., Ltd. was established in 1985 and is located in Dongguan City, primarily engaged in the manufacturing of computers, communications, and other electronic devices [1] - The company has a registered capital of 8.31821175 billion yuan and a paid-in capital of 6.23095241 billion yuan [1] - The legal representative of the company is Deng Chunhua [1] Investment and Intellectual Property - Shengyi Electronics has made investments in 3 external companies and participated in 63 bidding projects [1] - The company holds 15 trademark registrations and 616 patent registrations, along with 120 administrative licenses [1]